Skip to main content
. 2020 Jan 17;12(1):228. doi: 10.3390/cancers12010228

Figure 5.

Figure 5

Inhibition of OTS-412 replication by ganciclovir (GCV) in vivo. (A) (Study STG) Bioluminescence assay of viral replication in HCT 116 tumor tissue on day 7, post a single-dose injection of saline, OTS-412 (day 0, intratumoral [IT], 1 × 106 PFU), or OTS-412 + GCV (day 0, IT, 1 × 106 PFU + once/day, day -3 to 11, intraperitoneal [IP], 25 mg/kg, respectively). The histogram shows qPCR quantification of virus copy number in tumor tissue harvested on day 12 from the abovementioned study. (B) (Study MVG) Immunofluorescence assay shows viral replication in HCT 116 tumor tissue on day 21, after multiple doses of saline, OTS-412 (on day 0, 3, 7, 10, and 14, IP, 1 × 108 PFU), or OTS-412 + GCV (0, 3, 7, 10, and 14, IP, 1 × 108 PFU + once/day, day 0 to 20, IP, 50 mg/kg/mice, respectively). Green staining is from vaccinia virus (VACV) specific antibody (A27L) representing OTS-412 infected cells, blue staining is from cell nuclei. Images are shown at ×100 magnification.